Treatment with Ketamine

Phase 2

UUniversity of Maryland, Baltimore

Treatment with Ketamine is one of 36 therapeutic programs targeting Opioid Use Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Opioid Use DisorderRecruiting

Opioid Use DisorderPhase 2

Recruiting

Competition

Competitive Landscape

48 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Suboxone

IIndivior Inc.

Approved

20 2

Sovaldi

Gilead

Approved

1 3

Dolophine

HHikma Pharmaceuticals LLC

Approved

6 4

Cabenuva

Oxycontin

3 6

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

3 7

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 8

Lucemyra

BBioCorRx Pharmaceuticals Inc

Approved

2 9

Narcan

SScienture

Approved

2 10

Rayos

RRoxane Laboratories

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Opioid Use Disorder

NCT06943859

Clinical

Trials by Indication[1]

Opioid Use Disorder1 trial

Ketamine for the Treatment of Opioid Use Disorder

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06943859·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Treatment with Ketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Treatment with Ketamine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity of Maryland, Baltimore

Treatment with Ketamine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Opioid Use Disorder1 trial

References

Drug Info

Quick Facts

Related News